Table 2.
Dose-stratified vaccine efficacy against incident HPV16/18 infection (one-time detection, six-month persistence, and 12-month persistence) for women in the modified total vaccinated cohort (CVT and PATRICIA combined).
| Doses, no. | Arm | Women, no. | Events, no. | Person years | Rate per 100 PY (95%CI) | Vaccine Efficacy |
|---|---|---|---|---|---|---|
| Incident one-time detection of HPV16/18 | ||||||
| 3 (standard regimen) | HPV | 11110 | 529 | 43140 | 1·23 (1·12 to 1·34) | 77·0% (74·7 to 79·1%) |
| Control | 11217 | 2172 | 40682 | 5·34 (5·12 to 5·57) | ||
| 2 | HPV | 611 | 22 | 2538 | 0·87 (0·56 to 1·29) | 76·0% (62·0 to 85·3%) |
| Control | 574 | 82 | 2271 | 3·61 (2·89 to 4·46) | ||
| 1 | HPV | 292 | 8 | 1220 | 0·66 (0·30 to 1·25) | 85·7% (70·7 to 93·7%) |
| Control | 251 | 45 | 982 | 4·58 (3·38 to 6·08) | ||
| Incident detection of HPV16/18 that persisted ≥6 months | ||||||
| 3 | HPV | 11104 | 114 | 43706 | 0·26 (0·22 to 0·31) | 89·1% (86·8 to 91·0%) |
| Control | 11209 | 1000 | 41913 | 2·39 (2·24 to 2·54) | ||
| 2 | HPV | 611 | 4 | 2573 | 0·16 (0·05 to 0·38) | 89·7% (73·3 to 96·9%) |
| Control | 574 | 35 | 2308 | 1·52 (1·07 to 2·09) | ||
| 1 | HPV | 292 | 1 | 1234 | 0·08 (0·00 to 0·40) | 96·6% (81·7 to 99·8%) |
| Control | 250 | 24 | 1017 | 2·36 (1·55 to 3·46) | ||
| Incident detection of HPV16/18 that persisted ≥12 months | ||||||
| 3 | HPV | 11104 | 84 | 43775 | 0·19 (0·15 to 0·24) | 87·0% (83·7 to 89·7%) |
| Control | 11203 | 627 | 42589 | 1·47 (1·36 to 1·59) | ||
| 2 | HPV | 611 | 3 | 2576 | 0·12 (0·03 to 0·32) | 89·6% (68·9 to 97·5%) |
| Control | 574 | 26 | 2324 | 1·12 (0·75 to 1·62) | ||
| 1 | HPV | 292 | 1 | 1234 | 0·08 (0·00 to 0·40) | 95·1% (73·2 to 99·8%) |
| Control | 249 | 17 | 1021 | 1·67 (1·00 to 2·61) | ||